Skip to main content
Premium Trial:

Request an Annual Quote

Mitra Biotech Garners CLIA Certification for US Lab

NEW YORK (GenomeWeb) – Mitra Biotech announced today that it received CLIA certification for its laboratory in Woburn, Massachusetts.

The federal lab certification allows the company to launch its flagship product, CANScript, in the US. The platform replicates a cancer patient's tumor microenvironment and predicts which treatments will improve outcomes. Mitra said it is planning a US commercial launch in early 2017.

"This demonstrates our ongoing dedication to stringent quality standards, and opens the door for CANScript to deliver personalized treatment prediction information to US patients at a critical point in their treatment path, as well as actionable information to drive more effective cancer drug development," Mitra CEO Mallikarun Sundaram said in a statement.

The company also has certification from the National Accreditation Board for Testing and Calibration Laboratories for a lab facility in India, where CANScript is available in a number of cities.

Last year, Mitra raised $27.4 million in a Series B financing round, which the firm said it would use to expand the availability of the test.